HS
CRL icon

HighVista Strategies’s Charles River Laboratories CRL Stock Holding History

HighVista Strategies’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,200
Closed -$342K – 162
2018
Q1 		$342K Sell
3,200
-300
-9% -$32.3K 0.15% 103
2017
Q4 		$383K Sell
3,500
-1,200
-26% -$131K 0.11% 140
2017
Q3 		$508K Sell
4,700
-1,000
-18% -$103K 0.12% 125
2017
Q2 		$577K Sell
5,700
-2,400
-30% -$221K 0.13% 111
2017
Q1 		$729K Sell
8,100
-3,000
-27% -$255K 0.16% 128
2016
Q4 		$846K Buy
+11,100
New +$843K 0.17% 141

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HighVista Strategies's CRL Position: Q2 2018 in Review

HighVista Strategies sold out of Charles River Laboratories (CRL) in Q2 2018, closing a stake of 3,200 shares — an estimated $342K sold.

HighVista Strategies first reported a position in CRL in Q4 2016 and held it in 6 quarters. The position peaked at $846K in Q4 2016. 348 funds tracked by Wall St. Rank hold CRL as of Q2 2018.

  • HighVista Strategies reported no remaining Charles River Laboratories position as of Q2 2018 after selling out during the quarter.
  • HighVista Strategies sold 3,200 Charles River Laboratories shares in Q2 2018, an estimated $342K.
  • HighVista Strategies first reported a position in Charles River Laboratories in Q4 2016 and held it in 6 quarters.
  • HighVista Strategies's Charles River Laboratories position peaked at $846K in Q4 2016.
  • 348 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2018.

Based on HighVista Strategies's 13F filing for Q2 2018, filed 14 Aug 2018.